Sarepta Therapeutics Inc
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Sarepta Therapeutics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 14.90 $ to 24.50 $ · Last price: 20.70 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Sarepta Therapeutics Inc SRPT | 2.2 | 54.1 | 16.9 | 19.1 | 49.1 | 15.6 | 21.2 |
| Vertex Pharmaceuticals Inc VRTX | 130.6 | 31.3 | 24.5 | 55.0 | 38.1 | 9.6 | 33.4 |
| Regeneron Pharmaceuticals Inc REGN | 82.0 | 19.9 | 13.1 | 44.5 | 20.7 | 1.0 | 35.5 |
| Moderna Inc MRNA | 62.7 | – | 4.6 | -66.0 | -131.1 | -39.2 | 532.3 |
| argenx NV ARGX | 61.9 | 38.1 | 34.2 | 59.1 | 32.0 | 89.6 | 30.9 |
| Revolution Medicines Inc RVMD | 40.9 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 338.3 |
| BeiGene, Ltd. ONC | 40.0 | 63.1 | 34.1 | 88.9 | 19.1 | 40.2 | 6.4 |
| Alnylam Pharmaceuticals Inc ALNY | 32.6 | 61.8 | 28.4 | 79.7 | 23.0 | 65.2 | -48.1 |
| Royalty Pharma Plc RPRX | 32.5 | 31.8 | 19.6 | 95.8 | 100.3 | 5.1 | 68.6 |
| Median of companies shown | 40.9 | 38.1 | 19.6 | 55.0 | 23.0 | 9.6 | 33.4 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 5 | -267 | -267 | -5.49 | -246 | 337 | 424 |
| 2017 | 155 | -172 | -51 | -0.86 | -232 | 789 | 1,308 |
| 2018 | 301 | -344 | -362 | -5.46 | -389 | 1,032 | 1,642 |
| 2019 | 381 | -706 | -715 | -9.71 | -456 | 818 | 1,823 |
| 2020 | 540 | -564 | -554 | -7.11 | 107 | 762 | 2,985 |
| 2021 | 702 | -460 | -419 | -5.15 | -443 | 928 | 3,148 |
| 2022 | 933 | -536 | -703 | -8.03 | -325 | 385 | 3,128 |
| 2023 | 1,243 | -268 | -536 | -5.80 | -501 | 859 | 3,265 |
| 2024 | 1,902 | 218 | 235 | 2.18 | -206 | 1,528 | 3,963 |
| 2025 | 2,198 | -658 | -713 | -6.81 | -205 | 1,141 | 3,350 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 1.47 | 239.10 | 658 | 65.90 | 24.20 | 92 | 54 |
| 2025: Q1 | -4.60 | -1,361.30 | 745 | 80.20 | -60.10 | -583 | -629 |
| 2025: Q2 | 1.85 | 2,734.10 | 611 | 68.40 | 32.20 | 261 | 229 |
| 2025: Q3 | -1.80 | -636.50 | 399 | -14.50 | -45.10 | -15 | -43 |
| 2025: Q4 | -3.93 | -367.30 | 443 | -32.70 | -63.90 | 131 | 125 |
| 2026: Q1 | 2.71 | – | 731 | -1.90 | 45.30 | -203 | -206 |
| 2026: Q2 | -0.05 | -102.70 | 401 | -34.30 | -1.20 | 197 | 197 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Quality & Balance Sheet
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 4.44 | 2.88 – 6.00 | 1,837 | 187.9% | 11 |
| 12/31/2027 | 2.57 | 0.99 – 4.79 | 1,381 | -42.1% | 11 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 33.1%
- More than 10% revenue growth is expected for the coming year -22.5%
- Share count grows by less than 3% a year 6.2%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 1.6%
- Gross margin at 40% or higher and without meaningful erosion 59.9%
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 102 m
- Return on capital at 15% or higher, or up versus two years ago -29.2%
- Insiders hold at least 10% or are net buyers 4.2%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 94.9%
- Exp. sales growth 3Y > 5% -20.7%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% -20.7%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 1
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% -64.2%
- ROCE > 15% -29.2%
- Expected return > 10% -31.8%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 4, 2026 | Wong Ryan Ho-Yan | Chief Financial Officer | Other | 13,272 | 22.22 | 294,904 |
| Sep 4, 2026 | Estepan Ian Michael | Chief Operating Officer | Other | 24,799 | 22.22 | 551,034 |
| Sep 4, 2026 | Rothfuss Cristin | EVP, General Counsel | Other | 22,025 | 22.22 | 489,396 |
| Sep 4, 2026 | Rodino-Klapac Louise | President, R&D and Tech Ops | Other | 21,423 | 22.22 | 476,019 |
| Jul 28, 2026 | Severino Michael | Chief Executive Officer | Other | 756,104 | – | – |
The company
About the Company
Sarepta Therapeutics, Inc., ein biopharmazeutisches Unternehmen in der kommerziellen Phase, konzentriert sich auf Entdeckung und Entwicklung von RNA-gerichteten Therapeutika, einer siRNA-Plattform, Gentherapie und anderen genetischen Therapiemodalitäten zur Behandlung seltener Erkrankungen.
- Employees
- 835
- Headquarters
- Cambridge, MA
- Address
- 215 First Street, 02142 Cambridge, United States
- Phone
- 617 274 4000
- Website
- sarepta.com
- IPO Date
- 06/03/1997
- ISIN
- US8036071004
- Stock Split
- 1:6 on 07/12/2012
Management
| Name | Title | Birth Year |
|---|---|---|
| Ian Michael Estepan | President & COO | 1976 |
| Ryan H. Wong | Executive VP & CFO | 1979 |
| Cristin L. Rothfuss J.D. | Executive VP, General Counsel & Company Secretary | 1968 |
| Douglas S. Ingram Esq., J.D. | Advisor | 1963 |
| Louise R. Rodino-Klapac Ph.D. | President of Research & Development and Technical Operations | 1978 |
| Michael E. Severino M.D. | CEO & Director | 1966 |
| Rachael Potter Ph.D. | Chief Scientific Officer | – |
| Tamara Thornton | Director of Finance, Treasury & Investor Relations | – |
| Alison Nasisi | Executive VP & Chief People Officer | – |
| Diane L. Berry Ph.D. | Executive VP and Chief of Global Policy & Advocacy Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 08/05/2026 Sarepta Therapeutics, Inc. (SRPT): Results of Operations and Financial Condition; Financial Statements and Exhibits SEC ↗
- 07/27/2026 Sarepta Therapeutics, Inc. (SRPT): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.